심장 조직 공학 시장 - 시장 규모, 점유율, 동향 : 재료별, 제품별, 용도별, 최종 사용자별, 지역별 - 예측(-2029년)

The global cardiac tissue engineering market is projected to reach USD 1,333.6 Million by 2029 from USD 621.2 Million in 2024, at a CAGR of 16.5% from 2024 to 2029. The growth of the market is driven Technological advancement in 3d bioprinting. The market also benefits from the up surge in prevalence of cardiovascular diseases across the globe. However, high cost associated with treating cardiovascular diseases by cardiac tissue engineering process, is impacting the growth of the market. Moreover, the stringent regulatory policies in the field of cardiac tissue engineering are a major factor restraining the market growth.

"Hydrogel based scaffolds segment to witness the significant growth during the forecast period."

Based on material, the segment is divided into stem cells, and scaffolds. The scaffolds segment is further divided into synthetic scaffolds and biological scaffolds. The biological scaffolds are further segmented into collagen-based scaffolds and hydrogel-based scaffolds. In 2023, among these two biological scaffolds, the hydrogel-based scaffolds accounts for the significant share in cardiac tissue engineering market. This is due to their versatile properties that closely mimic natural tissue characteristics. Hydrogels are composed of highly hydrated networks, like the extracellular matrix, which promotes cell attachment, proliferation, and differentiation critical for tissue regeneration. Their mechanical properties can be tailored across a wide range to match those of specific tissues, enhancing compatibility and integration within the body. This tunability allows for the design of scaffolds with optimal porosity, biodegradability, and permeability, facilitating nutrient and oxygen diffusion essential for cell survival and tissue development. Moreover, hydrogels can be engineered to deliver bioactive molecules and growth factors in a controlled manner, further supporting tissue regeneration processes. Compared to collagen-based scaffolds, which also offer biological compatibility but have more limited mechanical tunability, hydrogels provide a superior platform for creating complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications. These advantages position hydrogel-based scaffolds as the preferred choice, driving their dominance in the biological scaffold segment of the scaffold market.

The segment is separated into scaffolds and stem cells based on the type of material. The material used on scaffolds is subdivided into two categories: biological scaffolds and synthetic scaffolds. Collagen- and hydrogel-based scaffolds are two further categories into which the biological scaffolds are divided. By 2023, the hydrogel-based biological scaffolds will have a larger market share in cardiac tissue engineering than the other two biological scaffolds combined. This is because of its adaptable qualities, which closely resemble those of natural tissue. Similar to the extracellular matrix, hydrogels are made of highly hydrated networks that support cell adhesion, proliferation, and differentiation-all of which are essential for tissue regeneration. Their ability to modify their mechanical characteristics to a large degree in order to match the characteristics of particular tissues improves their compatibility and integration with the body. dominance in the scaffold market's biological scaffold sector. Because of its tunability, scaffolds with the ideal porosity, biodegradability, and permeability may be designed, enabling the flow of nutrients and oxygen-both of which are necessary for tissue formation and cell survival. Hydrogels can also be designed to supply growth factors and bioactive compounds in a regulated way, which will aid in the processes involved in tissue regeneration. For the creation of complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications, hydrogels offer a superior platform than collagen-based scaffolds, which likewise offer biological compatibility but have less mechanical tunability. Because of these benefits, hydrogel-based scaffolds are positioned as the best option and dominate the market for biological scaffolds.

"Congenital heart disease treatment segment accounted for the significant share in the cardiac tissue engineering market during the forecast period."

Based on application, the cardiac tissue engineering market is segmented into myocardial infarction, heart valve repair/replacement, congenital heart disease treatment and others. Among these in 2023, the congenital heart disease treatment accounted for significant share. This is attributed to the rising prevalence and critical medical needs associated with congenital heart defects globally. For instance, in Australia, approximately 65,000 individuals live with congenital heart disease, with around 5,900 cases diagnosed annually as the principal cause. This condition also accounts for 79 infant deaths annually, highlighting its severe impact on public health. Similarly, in the United States, nearly 40,000 infants are born with congenital heart defects each year, underscoring the substantial patient population requiring advanced treatment options. Cardiac tissue engineering offers promising solutions for congenital heart defects by providing tailored approaches to repair or replace defective heart tissues. These innovations are crucial in addressing the specific anatomical and physiological challenges presented by congenital heart diseases, which often require personalized and durable interventions from early infancy throughout adulthood. The increasing incidence of congenital heart defects globally drives demand for innovative therapies that can improve patient outcomes and quality of life, thereby bolstering the congenital heart disease segment's prominence in the cardiac tissue engineering market.

The cardiac tissue engineering market is divided into segments based on application, comprising treatment for congenital heart disease, myocardial infarction, and heart valve repair/replacement. Treatment for congenital cardiac disease accounted for a sizable portion of these in 2023. This is explained by the increased global prevalence of congenital cardiac abnormalities and the urgent medical needs they provide. For example, congenital heart disease affects about 65,000 people in Australia, with 5,900 new instances being diagnosed as the primary cause each year. Its devastating influence on public health is further evidenced by the 79 newborn fatalities that are attributed to this illness each year. Comparably, over 40,000 babies in the US are born with congenital cardiac abnormalities every year, highlighting the sizeable patient population in need of cutting-edge care. Cardiac tissue engineering provides customized methods for replacing or repairing damaged cardiac tissues, which presents promising remedies for congenital heart abnormalities. These advancements are essential for tackling the unique anatomical and physiological problems associated with congenital cardiac disorders, which frequently call for customized and long-lasting therapies from early childhood into adulthood. The need for novel treatments that can enhance patient outcomes and quality of life is being driven by the rising incidence of congenital heart problems worldwide. This is expected to increase the importance of the congenital heart disease segment in the cardiac tissue engineering market.

"APAC is estimated to register the highest CAGR during the forecast period."

In this report, the cardiac tissue engineering market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period attributed to increase in strategic collaborations and robust research initiatives. In June 2023, the establishment of the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), involving patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank, underscored a concerted effort across nine health systems in Asia to enhance heart health and mitigate cardiovascular disease (CVD) impacts. Moreover, the presence of esteemed research institutions such as the Heart Research Institute, dedicated to advancing cardiovascular disease pathophysiology and pioneering tissue engineering solutions, enhances the region's capability to innovate in cardiac health technologies. With such collaborative frameworks and research capabilities, the Asia Pacific region is accelerating in scientific advancements for market growth in cardiac tissue engineering, promising significant opportunities for stakeholders in the sector.

.

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five main geographical regions into which the cardiac tissue engineering market is divided in the report. Due to a rise in strategic partnerships and active research projects, the APAC market is anticipated to grow at the fastest rate over the forecast period. The Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was founded in June 2023 and represents a coordinated effort across nine Asian health systems to improve heart health and lessen the effects of cardiovascular disease (CVD). Participants in the alliance include patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank. Furthermore, the region's capacity to innovate in heart health technologies is further enhanced by the existence of prestigious research organizations like the Heart Research Institute, which is committed to studying the pathophysiology of cardiovascular illness and developing innovative tissue engineering treatments. The Asia Pacific area is experiencing a notable surge in scientific developments for cardiac tissue engineering market growth, thanks to the presence of collaborative frameworks and research capacities. This presents substantial prospects for industry stakeholders.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW (16%)

List of Companies Profiled in the Report

• Terumo corporation (Japan)
• Artivion, Inc. (US)
• Baxter international, Inc. (US)
• Teijin Limited (Japan)
• Medtronic Plc. (Ireland)
• Boston Scientific Corporation (US)
• Abbott Laboratories (US)
• Merck KGaA (Germany)
• Elutia. (US)
• W. L. Gore & Associates, Inc. (US)
• Meril Lifesciences Pvt.Ltd (India)
• Fujifilm Holdings Corporation (Japan)
• Vascudyne, Inc. (US)
• BICO - THE BIO CONVERGENCE COMPANY (Sweden)
• ReproCELL, Inc. (US)
• PromoCell GmBH (Germany)
• Axol Bioscience Ltd. (UK)
• BPS Bioscience, Inc. (US)
• Cell Application, Inc. (US)
• Viscofan DE GmBH (Germany)

Research Coverage

This report studies the cardiac tissue engineering market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total cardiac tissue engineering market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (rising prevalence of cardiovascular diseases, increase in support from major market players and government bodies, Increased demand for regenerative medicine, the advancement of 3D bioprinting),restraints (High cost of treatment, Complex regulatory process), challenges (Safety concerns and complexity of biomaterials, Limited awareness and scarcity of skilled professionals), opportunities (Technological advancement in cardiac tissue engineering, The ability of biomaterials to enhance the functionality and integration of cardiac tissues offers significant opportunities, Increase in research of stems cells to treat cardiovascular diseases) contributing the growth of the cardiac tissue engineering market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the cardiac tissue engineering market.
• Market Development: Comprehensive information on the lucrative emerging markets, product, procedure, technology, application, end-user and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the cardiac tissue engineering market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global cardiac tissue engineering market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 MATERIAL DEFINITION
  • 1.2.2 PRODUCT DEFINITION
  • 1.2.3 APPLICATION DEFINITION
  • 1.2.4 END USER DEFINITION
  • 1.2.5 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
• 2.2 RESEARCH METHODOLOGY DESIGN
  • 2.2.1 SECONDARY RESEARCH
  • 2.2.2 KEY DATA FROM SECONDARY SOURCES
  • 2.2.3 PRIMARY DATA
  • 2.2.4 KEY DATA FROM PRIMARY SOURCES
  • 2.2.5 KEY INDUSTRY INSIGHTS
• 2.3 MARKET SIZE ESTIMATION
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ESTIMATION
• 2.6 STUDY ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 RESEARCH LIMITATIONS
  • 2.8.1 METHODOLOGY-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CARDIAC TISSUE ENGINEERING MARKET OVERVIEW
• 4.2 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION
• 4.3 REGIONAL SNAPSHOT OF CARDIAC TISSUE ENGINEERING MARKET (2023)
• 4.4 GEOGRAPHIC MIX: CARDIAC TISSUE ENGINEERING MARKET, 2024-2029 (USD MILLION)
• 4.5 CARDIAC TISSUE ENGINEERING MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of cardiovascular diseases
    • 5.2.1.2 Increase in support from major market players and government bodies
    • 5.2.1.3 Increased demand for regenerative medicine
    • 5.2.1.4 Advancements in 3D bioprinting
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of treatment
    • 5.2.2.2 Complex regulatory process
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements in cardiac tissue engineering
    • 5.2.3.2 Enhanced functionality and integration of cardiac tissues using biomaterials
    • 5.2.3.3 Increase in stem cell research to treat cardiovascular diseases
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Safety concerns and complexity of biomaterials
    • 5.2.4.2 Limited awareness and availability of skilled professionals
• 5.3 INDUSTRY TRENDS
  • 5.3.1 DEVELOPMENT OF BIOCOMPATIBLE AND BIODEGRADABLE MATERIALS
  • 5.3.2 INTEGRATION OF MICROFLUIDICS AND ELECTRICAL STIMULATION FOR IMPROVED CELL FUNCTION AND TISSUE MATURATION
  • 5.3.3 EXPANSION OF CARDIAC TISSUE ENGINEERING APPLICATIONS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
  • 5.4.2 STEM CELL TECHNOLOGY
  • 5.4.3 3D BIOPRINTING
  • 5.4.4 BIOREACTORS
  • 5.4.5 COMPLEMENTARY TECHNOLOGY
  • 5.4.6 GENE EDITING
  • 5.4.7 ELECTROSPINNING
  • 5.4.8 MICROFLUIDICS
  • 5.4.9 ADJACENT TECHNOLOGIES
    • 5.4.9.1 Biosensors
  • 5.4.10 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
  • 5.4.11 NANOTECHNOLOGY
• 5.5 PIPELINE ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 BUYING CRITERIA
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY ANALYSIS
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 PATENT ANALYSIS
  • 5.10.1 PATENT PUBLICATION TRENDS FOR CARDIAC TISSUE ENGINEERING MARKET
  • 5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
  • 5.11.2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2021 (USD MILLION)
  • 5.11.3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2021 (USD MILLION)
• 5.12 PRICING ANALYSIS
• 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.14 UNMET NEEDS IN CARDIAC TISSUE ENGINEERING MARKET
• 5.15 END USER EXPECTATIONS IN CARDIAC TISSUE ENGINEERING MARKET
• 5.16 AI INTEGRATION IN CARDIAC TISSUE ENGINEERING MARKET
• 5.17 ECOSYSTEM ANALYSIS
• 5.18 CASE STUDIES
• 5.19 SUPPLY CHAIN ANALYSIS
• 5.20 CARDIAC TISSUE ENGINEERING MARKET: INVESTMENT AND FUNDING SCENARIO
• 5.21 ADJACENT MARKET ANALYSIS
  • 5.21.1 TISSUE ENGINEERING MARKET

6 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL

• 6.1 INTRODUCTION
• 6.2 STEM CELLS
  • 6.2.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
• 6.3 SCAFFOLDS
  • 6.3.1 SYNTHETIC SCAFFOLDS
    • 6.3.1.1 Advancements in fabrication techniques to drive market
  • 6.3.2 BIOLOGICAL SCAFFOLDS
  • 6.3.3 COLLAGEN-BASED SCAFFOLDS
    • 6.3.3.1 Biocompatibility of material - key driver
    • 6.3.3.2 Hydrogel-based scaffolds
      • 6.3.3.2.1 Low mechanical strength to restrain segment growth

7 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 VASCULAR GRAFTS
  • 7.2.1 INCREASE IN PREVALENCE OF CORONARY ARTERY DISEASE TO DRIVE MARKET
• 7.3 CARDIAC PATCHES
  • 7.3.1 INCREASE IN CLINICAL TRIALS FOR CARDIAC PATCHES TO BOOST MARKET
• 7.4 HEART VALVES
  • 7.4.1 INCREASE IN PREVALENCE OF VALVE REGURGITATION TO DRIVE MARKET

8 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 MYOCARDIAL INFARCTION
  • 8.2.1 IMPROVED STRUCTURAL INTEGRATION TO DRIVE MARKET GROWTH
• 8.3 HEART VALVE REPAIR/REPLACEMENT
  • 8.3.1 INCREASE IN INCIDENCE OF AORTIC STENOSIS TO DRIVE MARKET
• 8.4 CONGENITAL HEART DISEASE
  • 8.4.1 SIGNIFICANT INVESTMENT BY KEY MARKET PLAYERS TO DRIVE MARKET
• 8.5 OTHER APPLICATIONS

9 CARDIAC TISSUE ENGINEERING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & CLINICS
  • 9.2.1 ADVANCED INFRASTRUCTURE AND ACCESS TO CLINICAL TRIALS - KEY DRIVERS
• 9.3 ACADEMIC & RESEARCH INSTITUTES
  • 9.3.1 AVAILABILITY OF FUNDING FOR RESEARCH - KEY DRIVER
• 9.4 OTHER END USERS

10 CARDIAC TISSUE ENGINEERING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Increasing government grants for research to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Availability of funding for research on regenerative medicine to fuel market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 UK
    • 10.3.2.1 Fastest-growing market for cardiac tissue engineering in Europe
  • 10.3.3 GERMANY
    • 10.3.3.1 Rising prevalence of cardiovascular diseases - key driver
  • 10.3.4 FRANCE
    • 10.3.4.1 Increasing focus on regenerative medicine to boost market
  • 10.3.5 ITALY
    • 10.3.5.1 Insufficient research funding to restrain growth of market
  • 10.3.6 SPAIN
    • 10.3.6.1 Increase in R&D investment to drive market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Increasing aging population to drive market growth
  • 10.4.3 CHINA
    • 10.4.3.1 Major cardiac tissue engineering market in Asia Pacific
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing government initiatives for clinical trials in stem cell research to boost market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Growing government support to fuel market
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Advancements in technology and strong government support to drive market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Increase in prevalence of congenital heart disease to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Rapidly growing geriatric population - key driver
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 EXPANDING NETWORK OF ADVANCED HEALTHCARE FACILITIES TO SUPPORT MARKET GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.3 GCC COUNTRIES
    • 10.6.3.1 Increased inclination toward novel therapies - key driver
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 11.3 REVENUE SHARE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 VALUATION AND FINANCIAL METRICS OF HEALTHCARE SERVICE VENDORS
• 11.6 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023)
  • 11.6.1 STARS
  • 11.6.2 EMERGING LEADERS
  • 11.6.3 PERVASIVE PLAYERS
  • 11.6.4 PARTICIPANTS
  • 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.6.5.1 Company footprint
    • 11.6.5.2 Region footprint
    • 11.6.5.3 Application footprint
    • 11.6.5.4 Product footprint
    • 11.6.5.5 Material footprint
    • 11.6.5.6 End user footprint
• 11.7 COMPANY EVALUATION MATRIX, STARTUPS/SMES (2023)
  • 11.7.1 PROGRESSIVE COMPANIES
  • 11.7.2 RESPONSIVE COMPANIES
  • 11.7.3 DYNAMIC COMPANIES
  • 11.7.4 STARTING BLOCKS
  • 11.7.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
    • 11.7.5.1 Detailed list of key startups/smes
    • 11.7.5.2 Competitive benchmarking of key startups/SMEs
• 11.8 COMPETITIVE SCENARIO
  • 11.8.1 PRODUCT LAUNCHES
  • 11.8.2 DEALS
• 11.9 BRAND/PRODUCT COMPARATIVE ANALYSIS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 TERUMO CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Right to win
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses & competitive threats
  • 12.1.2 ARTIVION, INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 BAXTER INTERNATIONAL, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 TEIJIN LIMITED
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Right to win
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses & competitive threats
  • 12.1.5 MEDTRONIC PLC
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 BOSTON SCIENTIFIC CORPORATION
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 ABBOTT LABORATORIES
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
  • 12.1.8 MERCK KGAA
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 FUJIFILM HOLDINGS CORPORATION
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 BICO - THE BIO CONVERGENCE COMPANY
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 ELUTIA
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 W. L. GORE AND ASSOCIATES, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 MERIL LIFESCIENCES PVT. LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 VASCUDYNE, INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 REPROCELL, INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
• 12.2 OTHER PLAYERS
  • 12.2.1 AXOL BIOSCIENCE LTD.
  • 12.2.2 BPS BIOSCIENCE, INC.
  • 12.2.3 TAKARA BIO, INC.
  • 12.2.4 XELTIS
  • 12.2.5 VISCOFAN DE GMBH
  • 12.2.6 CELL APPLICATION, INC
  • 12.2.7 PROMOCELL GMBH

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS